Previous 10 | Next 10 |
Image source: The Motley Fool. Nevro Corp (NYSE: NVRO) Q3 2019 Earnings Call Nov 6, 2019 , 4:30 p.m. ET Operator Continue reading
Nevro (NYSE: NVRO ): Q3 GAAP EPS of -$0.58 beats by $0.26 . More news on: Nevro Corp., Earnings news and commentary, Healthcare stocks news, Read more ...
REDWOOD CITY, Calif. , Nov. 6, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today reported financial results for the third quarter ended September 30, 2019 . Rev...
AAOI , AEL , AIMT , ALB , ANGI , ANSS , ASRT , ATO , ATSG , AXGN , BAND , BIDU , BL , BNFT , BRKS , CECO , CNDT , COLL , CTL , CVNA , CXW , DAR , DCP , DVAX , DXCM , DXPE , EBS , ECPG , EGAN , ENS , EOG , EQH , ERI , ET , EVRG , EXPE , FG , FISV , FIT ...
REDWOOD CITY, Calif. , Nov. 5, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced it has received approval from the U.S. Food and Drug Administration (FDA...
Nevro (NYSE: NVRO ) initiated with Perform (Neutral) rating at Oppenheimer. More news on: Nevro Corp., Varex Imaging Corporation, ViewRay, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
REDWOOD CITY, Calif. , Oct. 10, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the Company will release its financial results for the third quarte...
This article is part of a series that provides an ongoing analysis of the changes made to Ole Andreas Halvorsen's 13F stock portfolio on a quarterly basis. It is based on Viking Global's regulatory 13F Form filed on 08/14/2019. Please visit our Tracking Ole Andreas Halvorsen's Viking Global...
Nevro (NYSE: NVRO ) has completed patient enrollment in its multicenter Randomized Controlled Trial (RCT) for the treatment of chronic pain for patients who suffer from Painful Diabetic Neuropathy (PDN). More news on: Nevro Corp., Healthcare stocks news, Read more ...
REDWOOD CITY, Calif. , Aug. 28, 2019 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain conditions, today announced that it has completed patient enrollment in its prospect...
News, Short Squeeze, Breakout and More Instantly...
Nevro to Report Second-Quarter 2024 Financial Results and Host Earnings Conference Call on August 6, 2024 PR Newswire REDWOOD CITY, Calif. , July 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-chan...
Nevro to Present at Truist Securities MedTech Conference PR Newswire REDWOOD CITY, Calif. , June 11 , 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chr...
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 PR Newswire REDWOOD CITY, Calif. , May 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the trea...